Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288 | AAPG Stock News
SOPHARMA AD - Notification from Ivan Badinski under Regulation 596/2014 for exercise of rights for issue of warrants with ISIN № BG4000002262
Ascentage Pharma presents four-year follow-up data on Olverembatinib for TKI-resistant/intolerant CML-CP at ASH 2025, reaffirming long-term efficacy and safety in a registrational Phase II study.
Ascentage Pharma presents Phase II China study on Lisaftoclax at ASH Annual Meeting, supporting NDA approval by NMPA in July 2025.
Ascentage Pharma’s Olverembatinib Shows Promise in Rare GIST Treatment
Ascentage Pharma Reports Revenue Decline Amidst Strategic Drug Approvals